BioSpace News Archive

Venock is developing a vascular closure system for large bore punctures (up to 30 Fr and larger) in vessels following transvenous catheter-based therapies such as atrial ablations, leadless pacemaker implantations, ECMO, and various structural heart therapies such as Mitral- and Tricuspid- Valve Repair and Replacement.

Medolife Rx, Inc., a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc., announced that it will hold a webcast and Q&A with the investment community on Tuesday, July 27, at 5 p.m. Eastern Daylight Time.

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia

The market is estimated to grow with a CAGR of 4.5% from 2016-2025.

The magnetic resonance imaging market is expected to reach US$ 7,955.1 Mn in 2025 from US$ 5,913.6 in 2017

The telehealth market was valued at US$ 17,289.9 million in 2017 and it is projected to reach US$ 52,897.2 million in 2025; it is expected to grow at a CAGR of 15.7% from 2016 to 2025.

POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its cash position and revenue for the second quarter and first half of 2021.

BIOMODEX®, the leader in bio-realistic haptic simulators for patient-specific rehearsal and physician training, today announced that its LAACS™ (Left Atrial Appendage Closure System) solution was used to perform a simulation ahead of a live case to be presented at the TVT Structural Heart Summit in Miami, FL.

Genmab A/S announces under reference to Section 30 of the Danish Capital Markets Act that Artisan Partners LimitedPartnership has informed us that, as of July 16, 2021, Artisan Partners Limited Partnershipholds the voting rights to 3,261,591 sharesin Genmab A/S, which amounts to 4.97% of the share capital and voting rights in Genmab A/S.

A first-of-its-kind study published today in AACC’s Clinical Chemistry journal shows that a new protocol for coronavirus testing can increase clinical labs’ testing capacity without sacrificing accuracy